Sanofi SA
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Contact
46, avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2024
Employees
87,994
Sanofi SA News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,452.70 | 136.00 | 1.64% |
CAC 40 | 7,258.10 | 16.38 | -0.23% |
DAX 40 | 19,838.04 | 46.71 | -0.23% |
Dow JONES (US) | 42,840.26 | 498.02 | 1.18% |
FTSE 100 | 8,062.37 | 22.24 | -0.28% |
HKSE | 19,876.84 | 156.14 | 0.79% |
NASDAQ | 19,572.60 | 199.83 | 1.03% |
Nikkei 225 | 39,161.34 | 459.44 | 1.19% |
NZX 50 Index | 12,988.03 | 83.92 | 0.65% |
S&P 500 | 5,930.85 | 63.77 | 1.09% |
S&P/ASX 200 | 8,201.60 | 134.60 | 1.67% |
SSE Composite Index | 3,351.26 | 16.81 | -0.50% |